Targets › ASPA
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Oct 2032.
Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. (UniProt, P45381)
Open in Phaseline: the race on ASPA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Aspa Therapeutics | AAV9 BBP-812 Adeno-associated virus serotype 9 (AAV9) delivering aspartoacylase (ASPA) gene | ASPA | Phase 1 | Canavan Disease | Oct 2032 |
Canavan Disease (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.